Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. QCOM
2. FDX
3. CBRS
4. USO
5. MU
6. SPY
7. KBH
8. HON
9. HTZ
10. GOOGL

Go back to Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

Theravance Biopharma (TBPH) PT Lowered to $18 at Needham & Company

August 24, 2021 6:24 AM EDT

Needham & Company analyst Joseph Stringer lowered the price target on Theravance Biopharma (NASDAQ: TBPH) to $18.00 (from $32.00) while maintaining a Buy rating.

The analyst commented, "TBPH announced yesterday the izencitinib Ph2b RHEA trial in Ulcerative Colitis (UC) failed to demonstrate efficacy vs... More

Theravance Biopharma (TBPH) falls 21% as trading resumes after a trial missed the primary endpoint

August 23, 2021 4:37 PM EDT

Theravance Biopharma (NASDAQ: TBPH) falls 21% as trading resumes after a trial missed the primary endpoint.

... More

Theravance Biopharma (TBPH) to resume trading at 4:35PM ET after a trial did not meet the primary endpoint

August 23, 2021 4:10 PM EDT

Theravance Biopharma (NASDAQ: TBPH) to resume trading at 4:35PM ET after a trial did not meet the primary endpoint.

... More